Recombinant Vibrio vulnificus UPF0319 protein VV2327 (VV2327)

Shipped with Ice Packs
In Stock

Description

Absence of Specific Mentions

The search results extensively discuss V. vulnificus virulence mechanisms, including:

  • MARTXVv (RtxA1): A multifunctional toxin critical for intestinal invasion and systemic spread .

  • VvhA Hemolysin: Induces apoptosis in endothelial cells and contributes to erythrocyte lysis .

  • Secretion Systems: Type III (T3SS) and Type VI (T6SS) systems linked to pathogenicity .

No references to UPF0319 family proteins or VV2327 appear in genetic profiles, virulence factor analyses, or vaccine development studies .

Potential Research Avenues

While VV2327 is not described in available literature, its classification as a UPF0319 family protein suggests it may belong to a hypothetical protein group with unknown or uncharacterized functions. To address this gap, consider:

ApproachRationale
Genomic DatabasesQuery V. vulnificus genomes (e.g., NCBI, UniProt) for UPF0319 homologs.
Functional StudiesInvestigate VV2327’s role in stress response, secretion, or host interaction.
Structural PredictionUse tools like AlphaFold2 to predict tertiary structure and binding partners.

Relevant Analogues in V. vulnificus

Though VV2327 is uncharacterized, other hypothetical proteins with similar annotations have been studied:

  • VC0734 (Malate Synthase A): Involved in metabolic pathways, downregulated in virulent strains .

  • VC0736 (Isocitrate Lyase): Critical for carbon metabolism under stress conditions .

These examples highlight the importance of functional genomics in elucidating roles of conserved hypothetical proteins.

Recommendations for Further Research

To explore VV2327’s role in V. vulnificus pathogenicity:

  1. Gene Deletion Mutants: Assess virulence attenuation in animal models.

  2. Protein Interactions: Identify binding partners via affinity chromatography or yeast two-hybrid assays.

  3. Structural Analysis: Determine if VV2327 shares motifs with known virulence factors (e.g., MARTXVv effector domains).

Product Specs

Form
Lyophilized powder

Note: While we prioritize shipping the format currently in stock, please specify your format preference in order notes for customized fulfillment.

Lead Time
Delivery times vary depending on the purchase method and location. Please contact your local distributor for precise delivery estimates.

Note: All proteins are shipped with standard blue ice packs unless dry ice shipping is specifically requested and approved in advance. Additional fees apply for dry ice shipping.

Notes
Avoid repeated freeze-thaw cycles. Store working aliquots at 4°C for up to one week.
Reconstitution
Centrifuge the vial briefly before opening to collect the contents. Reconstitute the protein in sterile, deionized water to a concentration of 0.1-1.0 mg/mL. For long-term storage, we recommend adding 5-50% glycerol (final concentration) and aliquoting at -20°C/-80°C. Our standard glycerol concentration is 50%, but this can be adjusted as needed.
Shelf Life
Shelf life depends on storage conditions, buffer composition, temperature, and protein stability. Generally, liquid formulations have a 6-month shelf life at -20°C/-80°C, while lyophilized forms have a 12-month shelf life at -20°C/-80°C.
Storage Condition
Upon receipt, store at -20°C/-80°C. Aliquot to prevent repeated freeze-thaw cycles.
Tag Info
Tag type is determined during the manufacturing process.

Tag type is determined during production. If a specific tag is required, please inform us, and we will prioritize its development.

Synonyms
VV2327UPF0319 protein VV2327
Buffer Before Lyophilization
Tris/PBS-based buffer, 6% Trehalose.
Datasheet
Please contact us to get it.
Expression Region
19-207
Protein Length
Full Length of Mature Protein
Purity
>85% (SDS-PAGE)
Species
Vibrio vulnificus (strain YJ016)
Target Names
VV2327
Target Protein Sequence
AM ISPVSGVKIL FANGTEVDEP LEPMEVDAKS AQLVVRYAAE LGSGSNQKVF DSAPFVITID NLSEDIKLYP PKVFSYEQAN REFNTSPKWR IEGVSGKEIS YSQEKLKGND GFMPYYGMEA LIAKHNEERG IVFSAGVVKA EVVTTDKMVE KPATTKNADA LVQLQHWYKQ ASTEERKAFR KWMVDQE
Uniprot No.

Q&A

What is Vibrio vulnificus and why is the UPF0319 protein VV2327 significant for research?

Vibrio vulnificus is a foodborne pathogen prevalent in coastal waters worldwide that causes severe septicemia with fatality rates exceeding 50% even with aggressive antibiotic therapy . The UPF0319 protein VV2327 belongs to a family of uncharacterized proteins identified in the V. vulnificus genome. While less studied than other V. vulnificus proteins like the multifunctional autoprocessing RTX (MARTXVv) protein, membrane proteins such as VV2327 often play crucial roles in bacterial pathogenicity, membrane integrity, and environmental adaptation . Research on VV2327 could potentially contribute to understanding virulence mechanisms and developing preventive strategies against this deadly pathogen.

How does the genomic context of VV2327 compare with other characterized Vibrio vulnificus membrane proteins?

Comparative genomic analysis of V. vulnificus strains reveals that membrane proteins often exist within conserved genetic contexts that provide clues about their function. For example, the genetic context of varG in strain VV2018 was found to be conserved with a sequence of approximately 3 kbp encoding ompV-varG-nodD . By analyzing the genomic neighborhood of VV2327 and comparing it with better-characterized membrane proteins like UPF0761 membrane protein VV0203, researchers can generate hypotheses about potential functional relationships. Methodologically, this requires:

  • Complete genome sequencing of multiple strains

  • Comparative genomic analysis using bioinformatics tools

  • Gene synteny analysis to identify conserved gene arrangements

  • Functional prediction based on co-occurrence patterns with genes of known function

What expression systems are most effective for recombinant production of VV2327?

Based on successful approaches with other V. vulnificus membrane proteins like VV0203, E. coli expression systems represent a practical starting point for VV2327 expression . A methodological approach would include:

  • Construct design with an N-terminal His-tag for purification

  • Selection of appropriate E. coli strains optimized for membrane protein expression

  • Optimization of induction conditions (temperature, inducer concentration, duration)

  • Small-scale expression tests before scaling up

  • Analysis of expression using SDS-PAGE and western blotting

The recombinant protein should be expressed as a full-length construct (similar to the 1-313 amino acid approach used for VV0203) to maintain functional integrity .

What purification strategies yield the highest purity and stability for VV2327?

Purification of membrane proteins like VV2327 requires specialized approaches to maintain protein stability and function. Drawing from protocols used for similar proteins:

Purification StepConditionsCritical Considerations
Cell LysisMechanical disruption with detergentDetergent selection crucial for solubilization
IMACTris/PBS-based buffer with 6% Trehalose, pH 8.0 Imidazole gradient optimization required
Size ExclusionSame buffer system to maintain stabilityPrevention of aggregation during concentration
Quality ControlSDS-PAGE with >90% purity target Multiple freeze-thaw cycles should be avoided

For long-term storage, lyophilization or storage in glycerol (5-50%) at -20°C/-80°C with aliquoting to avoid freeze-thaw cycles is recommended .

What experimental methods can determine the membrane topology of VV2327?

Understanding the membrane topology of VV2327 is crucial for functional characterization and requires multiple complementary approaches:

  • Computational prediction using algorithms like TMHMM, Phobius, and TOPCONS

  • Experimental validation using:

    • Cysteine accessibility methods with membrane-permeable and impermeable reagents

    • Reporter fusion approaches (PhoA/LacZ fusion analysis)

    • Protease protection assays

    • Fluorescence-based techniques with GFP fusions

  • Structural analysis using techniques adapted for membrane proteins

  • Comparative analysis with structurally characterized homologs

These methods collectively provide a comprehensive understanding of how VV2327 is oriented within the membrane, which is essential for hypothesizing about its function.

How can researchers investigate potential interactions between VV2327 and host factors?

Investigating host-pathogen interactions involving VV2327 requires systematic approaches:

  • Pull-down assays using recombinant His-tagged VV2327 with host cell lysates

  • Yeast two-hybrid or bacterial two-hybrid screening

  • Crosslinking studies followed by mass spectrometry

  • Surface plasmon resonance to quantify binding affinities

  • Infection models using wild-type and VV2327 knockout strains

  • Immunofluorescence microscopy to visualize localization during infection

These methodologies can help determine whether VV2327 contributes to virulence through direct interactions with host factors, similar to how other V. vulnificus proteins function during pathogenesis.

What methodologies should be used to evaluate VV2327 as a potential vaccine antigen?

Assessment of VV2327 as a vaccine candidate would follow a methodological framework similar to that used for RtxA1-C protein :

  • Recombinant expression and purification of full-length VV2327 or immunogenic fragments

  • Formulation with appropriate adjuvants (as demonstrated with RtxA1-C)

  • Administration to experimental animals following prime-boost regimens

  • Quantification of antibody responses using ELISA and immunofluorescence staining

  • Evaluation of T-cell responses through IFN-γ ELISpot assays

  • Challenge studies to assess protection against V. vulnificus infection

  • Measurement of bacterial load reduction in blood and tissues post-challenge

The RtxA1-C vaccination resulted in significant protection against lethal challenge with V. vulnificus, demonstrating that recombinant protein-based approaches can be effective against this pathogen .

How should researchers assess cross-protection between antibodies generated against VV2327 and other Vibrio species?

Cross-protection assessment requires systematic evaluation of antibody cross-reactivity:

  • Bioinformatic analysis to identify homologous proteins in related Vibrio species

  • Expression and purification of homologous proteins from various species

  • Cross-reactivity testing using:

    • Western blotting with anti-VV2327 antibodies

    • Competitive ELISA to quantify binding affinities

    • Surface plasmon resonance for kinetic analysis

  • In vitro neutralization assays with multiple Vibrio species

  • In vivo challenge studies in immunized animals with heterologous species

  • Analysis of binding epitopes through peptide arrays or hydrogen-deuterium exchange mass spectrometry

This methodological approach can determine whether VV2327-based immunization provides species-specific or broader protection against related Vibrio pathogens.

What strategies should be employed to investigate the role of VV2327 in Vibrio vulnificus pathogenesis using genomic approaches?

To investigate VV2327's role in pathogenesis, researchers should implement a multi-faceted genomic approach:

  • Comparative genomics across clinical and environmental isolates:

    • Analyze sequence conservation and variation in VV2327 across strains

    • Identify correlations between VV2327 variants and virulence phenotypes

    • Include VV2327 in pan-genome analyses to determine if it belongs to the core or accessory genome

  • Transcriptomic analysis:

    • Measure VV2327 expression under various conditions (host infection, environmental stress)

    • Identify co-regulated genes through RNA-Seq

    • Map the regulon controlling VV2327 expression

  • Functional genomics:

    • Generate VV2327 knockout mutants using CRISPR-Cas9 or allelic exchange

    • Perform phenotypic characterization under various conditions

    • Conduct global interaction mapping (genetic, protein) to identify functional networks

This integrated approach has proven successful in characterizing other V. vulnificus virulence factors .

How can structural biology approaches be optimized for membrane proteins like VV2327?

Structural characterization of membrane proteins like VV2327 presents unique challenges requiring specialized methodologies:

  • Construct optimization:

    • Design multiple constructs with varying N- and C-terminal boundaries

    • Consider fusion with crystallization chaperones (T4 lysozyme, BRIL)

    • Remove flexible regions that may impede crystallization

  • Expression optimization:

    • Test specialized expression systems for membrane proteins

    • Optimize detergent solubilization conditions

    • Consider native-like membrane mimetics (nanodiscs, lipid cubic phase)

  • Advanced structural methods:

    • X-ray crystallography in lipid cubic phase

    • Single-particle cryo-electron microscopy

    • Solid-state NMR for dynamic studies

    • Hydrogen-deuterium exchange mass spectrometry for conformational analysis

  • Computational approaches:

    • Homology modeling based on structurally characterized homologs

    • Molecular dynamics simulations in membrane environments

    • Integration of experimental constraints with computational predictions

These approaches collectively maximize the probability of successful structural characterization of challenging membrane proteins like VV2327.

What are the most common technical challenges in VV2327 research and how can they be addressed?

Research on membrane proteins like VV2327 faces several technical challenges:

ChallengeMethodological SolutionImplementation Details
Low expression yieldsExpression system optimizationTest multiple E. coli strains, consider eukaryotic systems for complex membrane proteins
Protein aggregationBuffer and detergent optimizationScreen detergent types/concentrations, include stabilizing agents like trehalose (6%)
Functional assaysDevelopment of robust activity testsDesign assays based on predicted function, utilize surrogate markers for activity
Antibody productionOptimized immunization strategiesUse peptide antigens for conserved epitopes, purified domains for larger antigens
Reproducibility issuesStandardized protocolsMaintain detailed documentation, control expression and purification parameters

Systematic approaches to these challenges significantly improve research outcomes with challenging membrane proteins like VV2327.

How can researchers troubleshoot issues with antibody specificity against VV2327?

Antibody specificity issues against membrane proteins like VV2327 require systematic troubleshooting:

  • Epitope analysis and design:

    • Use bioinformatic tools to identify unique, surface-exposed regions

    • Design synthetic peptides representing specific epitopes

    • Avoid regions with potential cross-reactivity with host proteins

  • Validation methodology:

    • Perform western blotting against recombinant protein and whole-cell lysates

    • Include knockout controls to confirm specificity

    • Test against closely related proteins to assess cross-reactivity

    • Conduct immunofluorescence with appropriate controls

    • Perform pre-absorption controls with recombinant antigen

  • Purification approaches:

    • Affinity purification against the immunizing antigen

    • Negative selection against cross-reactive antigens

    • Isotype-specific purification for reduced background

These methodological approaches significantly improve antibody specificity and research outcomes.

How does research on VV2327 complement other approaches to combat Vibrio vulnificus infections?

Research on VV2327 can be integrated with broader strategies against V. vulnificus:

  • Multi-antigen vaccine development:

    • Combine VV2327 with other proven antigens like RtxA1-C

    • Evaluate synergistic protection through multiple antigenic targets

    • Apply approaches similar to those used for MPXV proteins A29L, M1R, A35R, and B6R combination vaccines

  • Diagnostic development:

    • Include VV2327 in multiplex detection systems

    • Develop rapid antibody-based tests for environmental and clinical samples

    • Design nucleic acid-based detection methods targeting VV2327 gene

  • Therapeutic targeting:

    • Evaluate VV2327 as a target for antimicrobial development

    • Design inhibitors that disrupt VV2327 function

    • Consider passive immunization strategies with anti-VV2327 antibodies

This integrated approach leverages VV2327 research within the broader context of combating V. vulnificus infections.

What future research directions should be prioritized for advancing VV2327 knowledge?

Priority research directions for VV2327 should include:

  • Functional characterization:

    • Determine precise biological function through knockout studies

    • Identify interaction partners and signaling pathways

    • Elucidate role in bacterial physiology and pathogenesis

  • Structural biology:

    • Determine three-dimensional structure

    • Map functional domains and critical residues

    • Understand conformational dynamics in membrane environment

  • Translational applications:

    • Evaluate diagnostic potential based on conservation and immunogenicity

    • Assess vaccine potential through challenge studies

    • Explore therapeutic targeting opportunities

  • Ecological and evolutionary context:

    • Investigate presence and variation across environmental isolates

    • Understand selective pressures shaping VV2327 evolution

    • Examine horizontal gene transfer patterns involving VV2327

These prioritized directions would significantly advance understanding of VV2327 and its potential applications in addressing V. vulnificus infections.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.